other material
confidence high
sentiment positive
materiality 0.75
Syndax sells 13.8% royalty on Niktimvo (axatilimab) to Royalty Pharma for $350M upfront
Syndax Pharmaceuticals Inc
- Royalty Pharma acquires right to 13.8% of net sales of Niktimvo (axatilimab) in US and territories.
- Upfront payment of $350M; aggregate payments to Royalty Pharma capped at $822.5M.
- Royalty rate subject to adjustments based on future aggregate net sales.
- Syndax retains repurchase right upon change of control; events of default trigger mandatory repurchase at cap.